# Engineered immune cells show promise for liver cancer treatment

Researchers have developed CAR T cells that target GPC3, a protein found in liver cancer cells, and are armored with a modified TGF-beta receptor to resist tumor suppression. This new approach aims to improve immunotherapy effectiveness against hepatocellular carcinoma, a common and deadly liver cancer. The advance could lead to more potent treatments for patients with limited options.

**Importance:** 3/5

## Sources

### Science
- [Nature](https://www.nature.com/articles/s41586-026-10786-z) — 2026-07-15